目的 觀察利心丸聯(lián)合沙庫巴曲纈沙坦鈉治療慢性心力衰竭的臨床療效。方法 選取2018年1月-2019年12月在新野縣人民醫(yī)院治療慢性心力衰竭患者91例為研究對象，采用隨機數(shù)字表法將91例慢性心力衰竭患者分為對照組（46例）和治療組（45例）。對照組口服沙庫巴曲纈沙坦鈉片，50 mg/次，2次/d，后期根據(jù)患者具體病情，每2~4周倍增1次，直至200 mg/次，2次/d。治療組在對照組基礎(chǔ)上口服利心丸，3 g/次，3次/d。兩組患者連續(xù)治療4周。觀察兩組臨床療效，比較兩組的6 min步行實驗（6 MWT）、心功能指標、血清學指標。結(jié)果 治療后，治療組總有效率（95.56%）高于對照組（80.43%）（P<0.05）。治療后，兩組6 MWT均較治療前增加（P<0.05），且治療組6 MWT高于對照組（P<0.05）。治療后，兩組左心室射血分數(shù)（LVEF）、每搏輸出量（SV）、心輸出量（CO）較治療前均升高，且治療組LVEF、SV、CO高于對照組（P<0.05）。治療后，兩組患者心型脂肪酸結(jié)合蛋白（H-FABP）、細胞間黏附分子-1（ICAM-1）水平較治療前均降低（P<0.05），且治療組H-FABP、ICAM-1水平低于對照組（P<0.05）。結(jié)論 利心丸聯(lián)合沙庫巴曲纈沙坦鈉片治療慢性心力衰竭療效確切，可提高運動耐量，改善心功能，降低H-FABP、ICAM-1水平。

Objective To observe the clinical effect of Lixin Pills combined with Sacubitril Valsartan Sodium Tablets in treatment of chronic heart failure. Methods Patients (91 cases) with chronic heart failure in Xinye People's Hospital from January 2018 to December 2019 were randomly divided into the control group (46 cases) and the treatment group (45 cases). Patients in the control group were po administered with Sacubitril Valsartan Sodium Tablets, 50 mg/time, twice daily, after that, according to the specific condition of the patient, it was doubled every 2-4 weeks until 200 mg/time, twice daily. Patients in the treatment group were po administered with Lixin Pills on the basis of the control group, 3 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and 6 MWT, cardiac function indexes, and serological indexes in two groups were compared. Results After treatment, the total effective rate of the treatment group (95.56%) was higher than that of the control group (80.43%) (P<0.05). After treatment, 6 MWT in both groups increased significantly (P<0.05), and the 6 MWT in the treatment group was higher than that in the control group (P<0.05). After treatment, LVEF, SV, and CO in two groups were significantly increased, and LVEF, SV, and CO in the treatment group were higher than those in the control group (P<0.05). After treatment, the levels of H-FABP and ICAM-1 in two groups were significantly decreased (P<0.05), and the levels of H-FABP and ICAM-1 in the treatment group were lower than those in the control group (P<0.05). Conclusion Lixin Pills combined with Sacubitril Valsartan Sodium Tablets has clinical curative effect in treatment of chronic heart failure, can improve exercise tolerance, improve cardiac function, and reduce the level of H-FABP and ICAM-1.

R972